Postnatal steroid treatment and brain development

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 89, Issue 2, 2004, Pages

  Baud, O ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CORTICOSTERONE; DEXAMETHASONE; EXCITOTOXIN; METHYLPREDNISOLONE; STEROID;

ASSISTED VENTILATION; BRAIN GROWTH; BRAIN INJURY; CELL CULTURE; CELL DAMAGE; CELL MATURATION; CEREBRAL PALSY; CHILDHOOD MORTALITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL MODEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; META ANALYSIS; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PERINATAL PERIOD; POSTNATAL CARE; PREMATURITY; PRIORITY JOURNAL; REDUCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STEROID THERAPY; SURVIVAL RATE;

EID: 1542721747     PISSN: 00039888     EISSN: 13592998     Source Type: Journal    
DOI: 10.1136/adc.2003.028696     Document Type: Review

References (63)

1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50:515-25.
2. Crowley P, Chalmers I, Keirse MJNC. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 1990;97:133.
3. Consensus Development Panel. Effect of corticosteroids for fetal maturation on perinatal outcomes. National Institutes of Health Conference Statement. Bethesda, MD: US Department of Health and Human Services, Public Health Service. National Institutes of Health 1994 Feb 28-Mar 2;12:1-24.
4. Rennie JM, Wheater M, Cole TJ. Antenatal steroid administration is associated with an improved chance of intact survival in preterm infants. Eur J Pediatr 1996;155:576-9.
5. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2003:(1).
6. Haddad H, Hsia D, Gellis S. Studies on respiratory rate in the newborn. Its use in the evaluation of RDS in IDM. Pediatrics 1956;17:204-12.
7. Baden M, Bauer CR, Colle E, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. J Pediatr 1972;50:526-34.
8. Mammel MC, Green TP, Johnson DE, et al. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983;1:1356-8.
9. Avery GB, Fletcher AB, Kaplan M, et al. Controlled trial of dexamethasone in respirator dependent infants with bronchopulmonary dysplasia. Pediatrics 1985;75:106-11.
10. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1998;79:F26-33.
11. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate 1999;76(suppl 1):29-40.
12. Larroque B, Samain H. Groupe Epipage. Epipage study: mortality of very premature infants and state of progress at follow up. J Gynecol Obstet Biol Reprod 2001;30:S33-41.
13. Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU Network: 1996-1997. Pediatrics 2000;106:1070-9.
14. Lemons JA, Bouer CR, Oh W, et al. Very low birth weight outcomes of the National Institutes of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 2001;107:e1.
15. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998;53:81-94.
16. Halliday HL, Ehrenkranz RA. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1):CD001146.
17. Halliday HL, Ehrenkranz RA. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1):CD001144.
18. Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1):CD001145.
19. Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001;344:95-101.
20. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998;101:e7.
21. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000;83:F177-81.
22. O'Shea T, Kothadia J, Klinepeter K, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999;104:15-21.
23. Baud O. Is perinatal dexamethasone treatment safe in preterm infants? Dev Med Child Neurol 2001;86(suppl):23-5.
24. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001;1:1.
25. Halliday HL. Early postnatal dexamethasone and cerebral palsy. Pediatrics 2002;109:1168-9.
26. Romagnoli C, Zecca E, Luciano R, et al. A three-year follow up of preterm infants after moderately early treatment with dexamethasone. Arch Dis Child Fetal Neonatal Ed 2002;87:F55-8.
27. Romagnoli C, Zecca E, Luciano R, et al. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics 2002;109:e85.
28. Bos AF, Martijn A, van Asperen RM, et al. Qualitative assessment of general movements in high-risk preterm infants with chronic lung disease requiring dexamethasone therapy. J Pediatr 1998;132:300-6.
29. Kuban KC, Leviton A. Cerebral palsy. N Engl J Med 1994;330:188-95.
30. Inder TE, Huppi PS, Warfield S, et al. Periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term. Ann Neurol 1999;46:755-60.
31. Murphy BP, Inder TE, Huppi PS, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001;107:217-21.
32. Ajayi-Obe M, Saeed N, Cowan FM, et al. Reduced development of cerebral cortex in extremely preterm infants. Lancet 2000;356:1162-3.
33. Modi N, Lewis H, Al-Naqeeb N, et al. The effects of repeated antenatal glucocorticoid therapy on the developing brain. Pediatr Res 2001;50:581-5.
34. Howard H. Reductions in size and total DNA of cerebrum and cerebellum in adult mice after corticosterone treatment in infancy. Exp Neurol 1968;22:191-208.
35. Riva MA, Fumagalli F, Racagni G. Opposite regulation of basic fibroblast growth factor and nerve growth factor gene expression in rat cortical astrocytes following dexamethasone administration. J Neurochem 1995;64:2526-33.
36. Goodman CS, Tessier-Lavigne M. Molecular mechanisms in axon guidance and targeted recognition. In: Cowan WM, Jessell TM, Zipursky SL, eds. Molecular and cellular approaches to neural development. New York: Oxford University Press, 1997:108-78.
37. Saliba E, Marret S. Cerebral white matter damage in the preterm infant: pathophysiology and risk factors. Semin Neonatol 2001;6:121-33.
38. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997;42:1-8.
39. Yoon BH, Romero R, Yang SH, et al. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol 1996;174:1433-40.
40. Nelson KB, Dambrosia JM, Grether JK, et al. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998;44:665-75.
41. Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res 2001;50:553-62.
42. Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002;22:455-63.
43. Kauffman F, Seidler FJ, Slotkin TA. Prenatal dexamethasone exposure causes loss of neonatal hypoxia tolerance: cellular mechanisms. Pediatr Res 1994;35:515-22.
44. Tombaugh GC, Yang SH, Swanson RA, et al. Glucocorticoids exacerbate hypoxic and hypoglycaemic hippocampal injury in vitro. J Neurochem 1992;59:137-46.
45. Prodanov D, Mantchev G, Iliev A, et al. Effects of dexamethasone in rat neonatal model of axotomy-induced motoneuronal cell death. Arch Physiol Biochem 1998;106:355-61.
46. Tsubota S, Adachi N, Chen J, et al. Dexamethasone changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats. Anesthesiology 1999;90:515-23.
47. Tuor UI, Chuman PD, Del Bigio MR. Prevention of hypaxic-ischaemic damage with dexamethasone is dependent on age and not influenced by fasting. Exp Neurol 1995;132:116-22.
48. Flavin MP. Influence of dexamethasone on neurotoxicity caused by oxygen and glucose deprivation in vitro. Exp Neurol 1996;139:34-8.
49. Arquie C, Leroux P, Bodenant C, et al. Glucocorticoid treatment in an ischaemic-like excitotoxic model of periventricular leucomalacia in mice. Br J Obstet Gynaecol 2002;109:989-96.
50. McGowan JE, Sysyn G, Petersson KH, et al. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J Neurosci 2000;20:7424-9.
51. Tahraoui SL, Marret S, Bodenant C, et al. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol 2001;11:56-71.
52. Marret S, Gressens P, Evrard P. Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Proc Natl Acad Sci USA 1996;93:15463-8.
53. Schwab M, Antonow-Schlorke I, Kuhn B, et al. Effect of antenatal betamethasone treatment on microtubule-associated proteins MAP1B and MAP2 in fetal sheep. J Physiol 2001;530:497-506.
54. Weichsel ME. The therapeutic use of glucocorticoid hormones in the perinatal period. Potential neurological hazards. Ann Neurol 1977;46:364-6.
55. Benesova O, Pavlik A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain. Neuropharmacology 1989;28:89-97.
56. Flagel SB, Vazquez DM, Watson SJ Jr, et al. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response. Am J Physiol Regul Integr Comp Physiol 2002;282:R55-63.
57. Stone DJ, Walsh JP, Sebro R, et al. Effects of pre- and postnatal corticosterone exposure on the rat hippocampal GABA system. Hippocampus 2001;11:492-507.
58. Shi B, Rabin SJ, Brandoli C, et al. Dexamethasone induces hypertrophy of developing medial septum cholinergic neurons: potential role of nerve growth factor. J Neurosci 1998;18:9326-34.
59. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999;341:1190-6.
60. Baud O, Laudenbach V, Evrard P, et al. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001;50:706-11.
61. Watterberg KL, Gerdes JS, Gifford KL, et al. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104:1258-63.
62. Andre P, Thebaud B, Odievre MH, et al. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med 2000;26:1496-500.
63. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2003;(1):CD002058.